Journal of Experimental Therapeutics and Oncology

Editor-in-Chief: Dominic Fan
ISSN: 1359-4117 (print)
ISSN: 1533-869X (online)
80 pages/issue · 8.5" x 11"
Issue Coverage: Volume 4 (2004) - Present

Aims and Scope

The journal is devoted to the rapid publication of innovative preclinical investigations on therapeutic agents against cancer and pertinent findings of experimental and clinical oncology.

In the journal you will find review articles, original articles, and short communications on all areas of cancer research, including but not limited to preclinical experimental therapeutics; anticancer drug development; cancer biochemistry; biotechnology; carcinogenesis; cancer cytogenetics; clinical oncology; cytokine biology; epidemiology; molecular biology; pathology; pharmacology; tumor cell biology; and experimental oncology.

Papers concerning work on humans must comply with the principles of the declaration of Helsinki (1964). The approval of an ethical committee must then be stated on the manuscript. The editors reserve the right to reject a paper with questionable ethical justification.

The editors of the Journal of Experimental Therapeutics and Oncology invite your contributions.

Abstracted and Indexed in:

Excerpta Medica, EMBASE, Index Medicus/MEDLINE.

Congratulations to JETO Associate Editor Dr. Mina Bissell, 2010 winner of the American Italian Cancer Foundation-Prize forScientific Excellence in Medicine for “having changed the accepted paradigms in cancer research, for pioneering to create the field of Tumor Microenvironment, and for the courage to persist not only until it is well accepted but also put to clinical use.”